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BACKGROUND: Thymidylate synthase (TS), a key enzyme in the de novo synthesis of thymidine, is an important chemotherapeutic target
for malignant tumours including lung cancer. Although inhibition of TS has an antiproliferative effect in cancer cells, the precise
mechanism of this effect has remained unclear.
METHODS: We examined the effects of TS inhibition with an RNA interference-based approach. The effect of TS depletion on the
growth of lung cancer cells was examined using colorimetric assay and flow cytometry.
RESULTS: Measurement of the enzymatic activity of TS in 30 human lung cancer cell lines revealed that such activity differs among
tumour histotypes. Almost complete elimination of TS activity by RNA interference resulted in inhibition of cell proliferation in all
tested cell lines, suggestive of a pivotal role for TS in cell proliferation independent of the original level of enzyme activity. The
antiproliferative effect of TS depletion was accompanied by arrest of cells in S phase of the cell cycle and the induction of caspase-
dependent apoptosis as well as by changes in the expression levels of cyclin E and c-Myc. Moreover, TS depletion induced
downregulation of the antiapoptotic protein X-linked inhibitor of apoptosis (XIAP), and it seemed to activate the mitochondrial
pathway of apoptosis.
CONCLUSION: Our data provide insight into the biological relevance of TS as well as a basis for clinical development of TS-targeted
therapy for lung cancer.
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Thymidylate synthase (TS) is an essential enzyme that catalyses
the transfer of a methyl group from methylenetetrahydrofolate
to dUMP to generate dTMP (Carreras and Santi, 1995). The
subsequent phosphorylation of dTMP to dTTP provides a direct
precursor for DNA synthesis. The level of TS expression is
increased in highly proliferative cells, and an increased abundance
of TS in a broad range of tumours is associated with a poor
treatment response and prognosis (Costi et al, 2005). Transfection
of nontransformed cells with an expression vector for TS has also
been found to confer transformed-like behaviour, suggesting that
TS itself is a potential oncoprotein (Rahman et al, 2004). These
findings have led to TS being considered as a molecular target for
cancer therapy. To date, the antiproliferative effect of TS inhibition
has been examined mostly with the use of drugs such as
5-fluorouracil and its active metabolite 5-fluoro-dUMP, the former
of which is used in cancer chemotherapy. Although studies with
antisense oligodeoxynucleotides have also shown that depletion of
TS results in growth inhibition in human tumour cells (Ferguson
et al, 1999; Lin et al, 2001; Flynn et al, 2006), the underlying
mechanism of the antiproliferative effect of specific TS inhibition
has remained largely unknown.
Lung cancer is one of the most common forms of cancer
worldwide. Advanced lung cancer is treated by combination
chemotherapy, although further improvement in such therapy is
warranted. High levels of TS in tumours have been associated
with a poor response to TS-targeting agents in individuals with
advanced lung cancer (Oguri et al, 2005; Kubota et al, 2009; Ozasa
et al, 2009), although the biological relevance of TS in lung cancer
has remained to be well established. We have now abrogated both
the expression and activity of TS in lung cancer cells by the
application of RNA interference (RNAi). With this approach, we
investigated the precise mechanism of the antiproliferative effect
of TS depletion in lung cancer cells and further examined the
potential role of TS as a target for chemotherapeutic agents in
these cells. Our results provide a basis for the further development
of TS-targeted therapy in lung cancer patients.
MATERIALS AND METHODS
Cell culture and reagents
The human lung cancer cell lines A549, H1975, H1650, H358,
SW1573, H460, H1299, H520, Calu-1, H226, H82, H526, and H69
were obtained from American Type Culture Collection (Manassas,
VA, USA); PC9 and PC9/ZD were obtained as described previously
(Koizumi et al, 2005); PC3, LK2, PC1, EBC-1, PC10, HARA, SBC-3,
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sMS-1, COR-L47, STC-1, SBC-1, and RERF-LC-MA were obtained
from Human Science Research Resources Bank (Osaka, Japan);
Lu135 and Lu134B were from Riken Cell Bank (Tokyo, Japan); and
QG56 was obtained from Immuno-Biological Laboratories (Gunma,
Japan). All cells were cultured under a humidified atmosphere of
5% CO2 at 371C in RPMI 1640 medium (Sigma, St Louis, MO, USA)
supplemented with 10% fetal bovine serum. The pan-caspase
inhibitor ZVAD-FMK was from Wako (Osaka, Japan).
Assay of TS activity
Thymidylate synthase activity was quantified using tritiated
5-fluoro-dUMP binding assay (Spears et al, 1984). Cells were
harvested, diluted in 0.2 M Tris-HCl (pH 7.4) containing 20mM
2-mercaptoethanol, 15mM CMP, and 100mM NaF, and disrupted
by ultrasonic treatment. The cell lysate was centrifuged at 1600g
for 15min at 41C, and the resulting supernatant was centrifuged at
105000g for 1h at 41C. A portion (50ml) of the final supernatant
was mixed consecutively with 50ml of Buffer A (600mM NH4HCO3
buffer (pH 8.0), 100mM 2-mercaptoethanol, 100mM NaF, and
15mM CMP) and with 50ml of [6-
3H]5-fluoro-dUMP (7.8pmol)
plus 25ml of cofactor solution (50mM potassium phosphate buffer
(pH 7.4), 20mM 2-mercaptoethanol, 100mM NaF, 15mM CMP, 2%
bovine serum albumin, 2mM tetrahydrofolic acid, 16mM sodium
ascorbate, and 9mM formaldehyde). The resulting mixture was
incubated at 301C for 20min, after which the reaction was
terminated by the addition of 100ml of 2% bovine serum albumin
and 275mlo f1M HClO4 and by centrifugation at 1630g for 15min
at 41C. The resulting precipitate was suspended in 2ml of 0.5 M
HClO4, and the mixture was subjected to ultrasonic treatment
followed by centrifugation at 1600g for 15min at 41C. The final
precipitate was solubilised with 0.5ml of 98% formic acid, mixed
with 10ml of ACS II scintillation fluid, and assayed for radioactivity.
RNAi
Cells were plated at 50–60% confluence in six-well plates or 25cm
2
flasks and then incubated for 24h before transient transfection for
the indicated times with small interfering RNAs (siRNAs) mixed
with the Lipofectamine reagent (Invitrogen, Carlsbad, CA, USA).
The siRNAs specific for TS mRNA (TS-1, 50-CAAUCCGCAUCCA
ACUAUU-30; TS-2, 50-GCUCAGGAUUCUUCGAAAA-30; and TS-3,
50-AGCUCAGGAUUCUUCGAAA-30) and a nonspecific siRNA
(50-GUUGAGAGAUAUUAGAGUU-30) were obtained from Nippon
EGT (Toyama, Japan). The cells were then subjected to immuno-
blot analysis, flow cytometry, or assay of TS or caspase-3 activity.
Immunoblot analysis
Cells were washed twice with ice-cold phosphate-buffered saline
(PBS) and then lysed in a solution containing 20mM Tris-HCl
(pH 7.5), 150mM NaCl, 1mM EDTA, 1% Triton X-100, 2.5mM
sodium pyrophosphate, 1mM phenylmethylsulfonyl fluoride, and
leupeptin (1mgml
–1). The protein concentration of cell lysates was
determined using the Bradford reagent (Bio-Rad, Hercules, CA,
USA), and equal amounts of protein were subjected to SDS–
polyacrylamide gel electrophoresis on a 7.5 or 12% gel. The
separated proteins were transferred to a nitrocellulose membrane,
which was then exposed to 5% nonfat dried milk in PBS for 1h at
room temperature before incubation overnight at 41C either with
rabbit polyclonal antibodies to TS (1:1000 dilution; Santa Cruz
Biotechnology, Santa Cruz, CA, USA), b-actin (1:500 dilution,
Sigma), survivin (1:1000 dilution; R&D Systems, Minneapolis,
MN, USA), or c-Myc, poly(ADP-ribose) polymerase (PARP), Bcl-2,
Bcl-xL, Bax, Bak, X-linked inhibitor of apoptosis (XIAP), or
Omi/HtrA2 (all in a 1:1000 dilution and from Cell Signaling
Technology, Danvers, MA, USA) or with mouse monoclonal
antibodies to cyclin E (1:1000 dilution, Santa Cruz Biotechnology),
cytochrome c (1:1000 dilution, Cell Signaling Technology), to
Smac/Diablo (1:1000 dilution, Cell Signaling Technology). The
membrane was then washed with PBS containing 0.05% Tween 20
before incubation for 1h at room temperature with horseradish
peroxidase-conjugated goat antibodies to rabbit (Sigma) or mouse
(Santa Cruz Biotechnology) immunoglobulin G. Immune complexes
were finally detected with chemiluminescence reagents
(GE Healthcare, Little Chalfont, UK).
Growth inhibition assay in vitro (MTT assay)
Cells were plated at 50–60% confluence in 25cm
2 flasks and then
incubated for 24h before transient transfection with an siRNA
specific for TS mRNA or a control siRNA as described above.
The cells were then isolated by exposure to trypsin, transferred to
96-well flat-bottom plates, and cultured for 72h before the addition
of TetraColor One (5mM tetrazolium monosodium salt and 0.2mM
1-methoxy-5-methyl phenazinium methylsulfate; Seikagaku, Tokyo,
Japan) to each well and incubation for an additional 3h at 371C.
The absorbance at 490nm of each well was measured using
Multiskan Spectrum instrument (Thermo Labsystems, Boston,
MA, USA), and absorbance values were expressed as a percentage
of that for nontransfected control cells.
Cell cycle analysis
Cells were harvested, washed with PBS, fixed with 70% methanol,
washed again with PBS, and stained with propidium iodide
(0.05mgml
–1) in a solution containing 0.1% Triton X-100, 0.1mM
EDTA, and RNase A (0.05mgml
–1). The stained cells (B1 10
6)
were then analysed for DNA content using flow cytometer (FACS
Caliber; Becton Dickinson, Franklin Lakes, NJ, USA) and Modfit
software (Verity Software House, Topsham, ME, USA).
Assay of caspase-3 activity
The activity of caspase-3 in cell lysates was measured using CCP32/
Caspase-3 Fluometric Protease Assay kit (MBL, Woburn, MA,
USA). Fluorescence attributable to cleavage of the Asp-Glu-Val-
Asp-7-amino-4-trifluoromethyl coumarin (DEVD-AFC) substrate
was measured at excitation and emission wavelengths of 390 and
460nm, respectively.
Subcellular fractionation
A cytosolic fraction was isolated from cells by centrifugation. In
brief, cells were washed, resuspended in homogenisation buffer
(0.25 M sucrose, 10mM HEPES-NaOH (pH 7.4), and 1mM EGTA),
and homogenised by 50 strokes in a Dounce homogeniser. The
homogenate was centrifuged at 1000g for 15min at 41C to remove
nuclei and intact cells, and the resulting supernatant was
centrifuged at 10000g for 15min at 41C. The final supernatant
(cytosolic fraction) was subjected to immunoblot analysis.
Statistical analysis
Data were analysed using Student’s two-tailed t-test. A P-value of
o0.05 was considered statistically significant.
RESULTS
TS activity varies among histotypes of lung cancer cells
We first examined the enzymatic activity of TS in 30 human lung
cancer cell lines (Table 1). The median TS activity in small cell lung
cancer (SCLC) lines was significantly higher than that in non-SCLC
(NSCLC) lines. Among NSCLC cell lines, the values for squamous
cell carcinoma were higher than those for non-squamous cell
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scarcinoma (Figure 1). There was no significant correlation between
TS activity and cell proliferation rate among these lung cancer cell
lines (data not shown). These data thus suggested that TS activity
varies according to histotype among lung cancer cell lines.
TS depletion induces growth inhibition regardless of
original TS activity level in lung cancer cells
We next examined the effect of TS depletion by RNAi on the
growth of lung cancer cell lines. The abundance of TS was
markedly decreased as a result of cell transfection with either of
three different siRNAs targeted to TS mRNA (Figure 2A). Given
that the TS-1 siRNA induced the most pronounced downregulation
of TS expression, we selected this siRNA for use in subsequent
experiments. In all tested lung cancer cells, transfection with TS-1
resulted in marked depletion of TS, whereas no such effect was
observed in cells transfected with a nonspecific siRNA (Figure 2B).
Moreover, transfection of cells with TS-1 resulted in a 490%
decrease in TS activity compared with that in corresponding cells
transfected with a nonspecific siRNA or in untreated cells
(Figure 2C), regardless of the original levels of TS expression
and activity. The antiproliferative effect of TS depletion was
evaluated using the MTT assay. Depletion of TS resulted in
pronounced inhibition of proliferation in all tested cells compared
with the corresponding cells transfected with a nonspecific siRNA
or untreated cells (Figure 2D), and this antiproliferative effect was
found to be time dependent (Figure 2E). These data thus suggested
that the almost complete elimination of TS activity resulted in
marked inhibition of the proliferation of lung cancer cells
regardless of the original level of such activity.
TS depletion induces S-phase arrest in lung cancer cells
To investigate the mechanism by which TS depletion inhibits lung
cancer cell growth, we examined the cell cycle profile by flow
cytometry. Transfection with TS-1 siRNA increased the proportion
of cells in S phase of the cell cycle and reduced that of cells in G1 or
G2–M phases in all tested cell lines regardless of histotype
(Figure 3A). Immunoblot analysis of proteins implicated in
regulation of the G1–S transition revealed that TS depletion
increased the abundance of cyclin E in all tested cell lines
(Figure 3B) without affecting that of cyclins D or A (data not
shown). In addition, TS depletion induced downregulation of
c-Myc (Figure 3B), a transcription factor that activates the
expression of several cell cycle-related genes. However, expression
of c-Myc was not detected in H69 cells, consistent with previous
observations (Plummer et al, 1993). These results thus suggested
that the S-phase arrest induced by TS depletion in lung cancer
cells was related to upregulation of cyclin E and downregulation
of c-Myc.
TS depletion induces caspase-dependent apoptosis in lung
cancer cells
We next examined the effect of TS depletion on apoptosis in lung
cancer cells. Flow cytometric analysis revealed that TS depletion
induced a time-dependent increase in the size of the sub-G1
(apoptotic) cell population (Figure 4A). Depletion of TS also
induced the cleavage of PARP (Figure 4B), a characteristic of
apoptosis, in the cell lines examined. Furthermore, the activity of
caspase-3 in cell lysates was increased as a consequence of TS
depletion (Figure 4C), and previous exposure of lung cancer cells
to the pan-caspase inhibitor ZVAD-FMK significantly inhibited
the increase in the size of the sub-G1 cell population induced
by depletion of TS (Figure 4D). These data thus indicated that
TS depletion induces caspase-dependent apoptosis in lung
cancer cells.
TS depletion activates the mitochondrial pathway of
apoptosis and induces downregulation of XIAP
To elucidate further the mechanism of apoptosis induced by TS
depletion, we examined the expression of members of the Bcl-2
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Figure 1 Thymidylate synthase (TS) activity in lung cancer cell lines
stratified according to histotype. Central horizontal lines represent median
values, with the upper and lower bars representing the 95% confidence
interval. *Po0.05 for squamous cell carcinoma vs non-squamous cell
carcinoma; **Po0.05 for SCLC vs either squamous cell or non-squamous
cell carcinoma.
Table 1 TS activity of lung cancer cell lines classified according to
histology
Cell line Histology
TS activity
(pmol per mg protein)
A549 Adeno 1.003±0.142
H1975 Adeno 1.005±0.276
H1650 Adeno 0.705±0.177
PC9 Adeno 0.370±0.042
PC9/ZD Adeno 0.635±0.148
H358 Adeno 1.140±0.127
PC3 Adeno 0.591±0.325
SW1573 Adeno 1.695±0.544
H460 Large cell 0.420±0.184
H1299 Large cell 1.121±0.594
H520 Squamous 1.755±0.813
Calu-1 Squamous 4.805±3.061
H226 Squamous 1.930±0.820
LK2 Squamous 1.121±0.042
PC1 Squamous 3.055±0.997
EBC-1 Squamous 1.055±0.078
PC10 Squamous 1.204±0.052
QG56 Squamous 0.870±0.030
HARA Squamous 2.590±0.340
SBC-3 SCLC 5.795±0.247
H82 SCLC 5.170±0.641
H526 SCLC 1.125±0.092
H69 SCLC 4.005±0.078
MS-1 SCLC 2.555±0.474
COR-L47 SCLC 3.760±0.560
STC-1 SCLC 6.832±0.490
SBC-1 SCLC 0.753±0.023
Lu135 SCLC 3.698±0.190
Lu134B SCLC 0.310±0.100
RERF-LC-MA SCLC 1.413±0.183
Abbreviations: SCLC¼small cell lung cancer; TS¼thymidylate synthase. Data are
means±s.d. from three independent experiments.
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sand inhibitor of apoptosis (IAP) families of proteins, both of
which are important regulators of apoptotic signalling pathways
(Hengartner, 2000). Although depletion of TS did not substantially
affect the expression levels of Bcl-2, Bcl-xL, Bax, Bak, and survivin,
it resulted in a substantial decrease in the abundance of X-linked
inhibitor of apoptosis (XIAP) (Figure 5A). The activity of XIAP is
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Figure 2 Effects of transient depletion of TS on TS activity and the proliferation of lung cancer cell lines. (A) The indicated cell lines were transfected with
a nonspecific (NS) siRNA or with either of three different siRNAs specific for TS mRNA (TS-1, TS-2, and TS-3) for 48h, after which cell lysates were
prepared and subjected to immunoblot analysis with antibodies to TS and b-actin (loading control). (B) The indicated cell lines were left untreated (NT) or
were transfected with nonspecific or TS-1 siRNAs for 48h, after which cell lysates were prepared and subjected to immunoblot analysis with antibodiest o
TS and b-actin. (C) Cells were left untreated or were transfected with NS or TS-1 siRNAs for 72h, after which cell lysates were prepared and assayed for TS
activity. Data are expressed as a percentage of the value for untreated cells and are means±s.d. of triplicates from experiments that were repeated on at
least one additional occasion with similar results. (D) Cells were left untreated or were transfected with NS or TS-1 siRNAs for 72h, after which cell viability
was assessed with the MTT assay. Data are expressed as a percentage of the value for untreated cells and are means of triplicates from experiments that
were repeated on two additional occasions with similar results. (E) Cells were left untreated or were transfected with NS or TS-1 siRNAs for the indicated
times, after which cell viability was assessed with the MTT assay. Data are means±s.d. of triplicates from experiments that were repeated on two additional
occasions with similar results.
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smodulated by mitochondrial proteins such as cytochrome c, Smac
(also known as Diablo), and Omi (also known an HtrA2)
(Hengartner, 2000; Srinivasula et al, 2003; Martinez-Ruiz et al,
2008). To investigate the mechanism of the downregulation of
XIAP induced by TS depletion, we examined the release of these
mitochondrial proteins into the cytosol. Immunoblot analysis
revealed that the amounts of these mitochondrial proteins in the
cytosol were increased by TS depletion in a time-dependent
manner (Figure 5B). These data thus suggested that TS depletion-
induced apoptosis is mediated, at least in part, by the mitochon-
drial signalling pathway.
DISCUSSION
Studies of TS-targeted therapy as well as the role of TS in DNA
synthesis have provided the rationale for consideration of this
enzyme as a prime therapeutic target. However, the precise
mechanism by which inhibition of TS results in inhibition
of tumour cell growth has remained incompletely understood.
The aim of this study was therefore to investigate the underlying
mechanism of the antiproliferative effect of specific TS inhibition
in lung cancer cells with the use of an siRNA-based approach.
We first examined TS activity in lung cancer cell lines of
different histotypes. Thymidylate synthase activity was determined
with the use of the well-established 5-fluoro-dUMP binding assay.
We found that TS activity was significantly higher in SCLC lines
than in NSCLC lines, and that, among the latter, TS activity was
higher in squamous cell carcinoma lines than in non-squamous
cell carcinoma lines. A previous microarray analysis showed that
mRNAs for proliferation-related proteins including TS were more
abundant in SCLC lines than in NSCLC lines (Bhattacharjee et al,
2001). In addition, recent studies showed that the amount of TS
mRNA was higher in resection specimens from patients with
squamous cell carcinoma of the lung than in those from
individuals with other histotypes of NSCLC (Ceppi et al, 2006;
Ishihama et al, 2009; Monica et al, 2009). Given that TS activity in
lung cancer cell lines was proportional to the abundance of TS
protein in the present study (data not shown), our data showing a
differential profile of TS activity among histotypes of lung cancer
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Figure 3 Effects of TS depletion on cell cycle distribution and on cyclin E and c-Myc expression in lung cancer cells. (A) The indicated cell lines were
transfected with nonspecific (NS) or TS-1 siRNAs for 48 or 72h and were then fixed, stained with propidium iodide, and analysed for cell cycle distribution
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transfected with NS or TS-1 siRNAs for 72h, after which cell lysates were prepared and subjected to immunoblot analysis with antibodies to TS, cyclin E,
c-Myc, and b-actin. Transfection with the NS siRNA had no substantial effect on cell cycle distribution or on the expression of cyclin E or c-Myc compared
with untreated cells.
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sare consistent with these previous findings. The cell line SCLC
differs from NSCLC in terms of its faster growth and earlier spread
(Allen and Jahanzeb, 2008), and recent clinical trials in NSCLC
patients have revealed a poorer prognosis for squamous cell
carcinoma than for adenocarcinoma (Asamura et al, 2008). The
differential activity of TS among histotypes of lung cancer is thus
suggestive of a role for this enzyme in promoting cell proliferation,
with TS activity being a potential marker of tumour aggressiveness
in lung cancer, although TS activity was not correlated with cell
proliferation rate among the lung cancer cell lines examined in this
study. We induced downregulation of both TS abundance and
enzymatic activity in lung cancer cell lines by RNAi. The almost
complete elimination of TS activity was associated with a marked
antiproliferative effect in all tested lung cancer cell lines, including
those with an original relatively low level of TS activity. These data
suggest that TS is important for tumour cell proliferation in a
manner independent of the original activity level.
We found that depletion of TS induced S-phase arrest and
caspase-dependent apoptosis in lung cancer cells. Previous studies
have shown that TS inhibition results in an imbalance between
the amounts of dUTP and dTTP and a consequent decrease in
the efficiency of DNA synthesis (Curtin et al, 1991; Houghton
et al, 1993). Furthermore, this dUTP–dTTP imbalance results in
misincorporation of dUTP into DNA and consequent DNA damage
(Curtin et al, 1991; Houghton et al, 1993). In this study, we
examined the effect of TS depletion on DNA damage as determined
by immunofluorescence imaging of histone g-H2AX foci, a
sensitive and specific marker of DNA double-strand breaks
(Burma et al, 2001; Stiff et al, 2004). Such foci were detected in
B90% of lung cancer cells transfected with TS siRNA (Supple-
mentary Figure S1). Given that DNA damage or a reduced rate of
DNA synthesis triggers the S-phase checkpoint mechanism
(Sclafani and Holzen, 2007), the observed S-phase arrest induced
by TS depletion likely results from activation of the S-phase
checkpoint. Cellular responses to DNA damage are important for
maintenance of genomic stability and cellular integrity (Bunz et al,
1998; Hirao et al, 2000). Cells either repair DNA damage or, if it is
too severe for repair, initiate the cell death program (Zhao et al,
2001). Our data thus suggest that cells that arrest in S phase after
TS depletion subsequently undergo apoptosis as a result of the
accumulation of unrepairable DNA damage. We further showed
that TS depletion resulted in upregulation of cyclin E and
downregulation of c-Myc. Both cyclin E and c-Myc contribute to
the transition of cells from G1 to S phase (Wang et al, 2008;
Malumbres and Barbacid, 2009) and have recently been implicated
in promotion of caspase-dependent apoptosis subsequent to
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Figure 4 Effect of TS depletion on apoptosis in lung cancer cells. (A) The indicated cell lines were transfected with nonspecific (NS) or TS-1 siRNAs for
48 or 72h and were then fixed, stained with propidium iodide, and subjected to flow cytometry for quantitation of the sub-G1 population. Data are
means±s.d. of triplicates from experiments that were repeated on two additional occasions with similar results. (B) Cells were transfected with NS or TS-1
siRNAs for 72h, after which cell lysates were prepared and subjected to immunoblot analysis with antibodies to TS, PARP, and b-actin. The positions of
intact and cleaved forms of PARP are indicated. (C) Cells were transfected with NS or TS-1 siRNAs for 48 or 72h, lysed, and assayed for caspase-3 activity.
Data are expressed relative to the value for cells transfected with NS siRNA and are means±s.d. from three independent experiments. (D) Cells were
incubated for 2h with or without ZVAD-FMK (50mM), transfected with NS or TS-1 siRNAs for 48 or 72h (in the continued absence or presence of ZVAD-
FMK), and then evaluated for the size of the sub-G1 population as in (A). Data are means±s.d. of triplicates from experiments that were repeated on two
additional occasions with similar results. *Po0.05 for the indicated comparisons. Transfection with the NS siRNA had no substantial effects on these markers
of apoptosis compared with untreated cells.
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synthesis in tumour cells (Mazumder et al, 2000; Leonce et al,
2001; Lu et al, 2009; Sankar et al, 2009). The effects of TS depletion
on the abundance of cyclin E and c-Myc therefore likely contribute
to the associated S-phase arrest and caspase-dependent apoptosis
in lung cancer cells. Our present data thus suggest that the
antiproliferative effect of TS depletion is attributable to S-phase
arrest and the induction of caspase-dependent apoptosis in these
cancer cells.
Our investigation of the mechanism by which TS depletion led
to caspase-dependent apoptosis revealed that elimination of TS
resulted in downregulation of XIAP, a member of the IAP family of
proteins. Activation of the mitochondrial signalling pathway for
apoptosis results in inhibition of IAP proteins and consequent
promotion of caspase-dependent apoptosis (Hengartner, 2000;
Takasawa et al, 2005; Yu et al, 2007). We also found that TS
depletion resulted in the release of mitochondrial proteins, includ-
ing cytochrome c, Smac/Diablo, and Omi/HtrA2, into the cytosol,
suggestive of a link between activation of the mitochondrial pathway
and downregulation of XIAP in lung cancer cells depleted of TS.
Activation of the mitochondrial pathway is induced by a variety of
stimuli including DNA damage (Hengartner, 2000). Given that TS
depletion induced DNA double-strand breakage, our data suggest
that loss of TS may contribute to activation of the mitochondrial
pathway of apoptosis. We found that TS depletion did not affect the
expression level of the IAP protein survivin. Further study will thus
be needed to elucidate the precise mechanism by which XIAP is
downregulated specifically in TS-depleted cells.
In conclusion, we have shown that the almost complete
elimination of TS activity with an RNAi-based approach resulted
in an apparently universal antiproliferative effect in lung cancer
cells that was attributable to S-phase arrest and the induction of
apoptosis. High levels of TS expression have been suggested to
predict resistance to TS-targeted agents such as 5-fluorouracil
(Johnston et al, 2003; Showalter et al, 2008). The new TS-targeted
agent pemetrexed was found to have low activity in the treatment
of SCLC (Ceppi et al, 2006; Socinski et al, 2009), possibly as a
result of a high level of TS expression in such tumours. Our results
now suggest that TS depletion inhibits the growth of lung cancer
cells including SCLC cells with a high original activity of TS.
This apparent discrepancy may be explained by the fact that
5-fluorouracil and pemetrexed inhibit TS activity by only B60%
(van Triest et al, 1997, 1999; Codacci-Pisanelli et al, 2002;
Giovannetti et al, 2008), whereas our siRNA-based method inhibit
TS activity almost completely. Our present results thus suggest that
novel TS-targeted agents with an increased inhibitory efficacy
might prove beneficial for the treatment of lung cancer regardless
of histotype. They further provide a rationale for future clinical
investigation of the therapeutic efficacy of TS-targeted agents for
lung cancer patients.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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